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The problem of research waste in obstetrics 
Once awarded Archie Cochrane‟s infamous „wooden spoon‟ for the limited application of 
randomised controlled trial evidence to questions of clinical practice, obstetricians were inspired 
to action and ultimately became leaders in the development of evidence based medicine.(1) 
Although the importance of randomised controlled trials and the systematic synthesis of their 
results to clinical practice is now undisputed, concern has moved to the quality of the design 
and conduct of primary trials and observational studies, completeness of reporting and the 
relevance of the research to clinical practice.  
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It has been estimated that around 85% of all research funding is actually wasted, a staggering 
figure thought to be over USD $80 billion,(2) but the impact of research waste goes beyond 
misuse of finite financial resources. Incomplete reporting, duplicated work, poorly conducted 
trials, and delayed synthesis of existing evidence have led to substantial barriers in the 
identification of both beneficial new therapies and severe adverse effects associated with 
existing treatments, leading directly to patient harm.(3) As we seek to further integrate research 
within clinical settings, we must face the ethical implications of unaddressed research waste and 
commit to improving the quality of research in the same way that we strive to improve the quality 
of direct clinical care.  
 
In a landmark series in The Lancet , 17 recommendations for the reduction of research waste 
across five stages of research production, dissemination, and implementation were proposed in 
2014.(4–8) It is not our intention to revisit the comprehensive assessment and rationale of these 
recommendations, rather to consider how in the intervening years the field of obstetrics has 
responded to their challenges, identify those issues peculiar to our speciality in seeking to 
change the process of research production,  dissemination, and implementation for the better 
and explore avenues for future development (Figure 1).  
 
 
The ethical imperative for high value research in obstetrics 
 
Women are under-represented in clinical trials generally, and pregnant women especially so.(9) 
This does not stop women from developing health conditions during pregnancy that require 
treatment, and most medications administered in pregnancy, both over the counter and by 
prescription, are off-label and unlicensed for use in pregnancy.(10) The clinical use of drugs 










untested in pregnant women shifts the risk from monitored small populations in research 
contexts to uncounted and highly variable use in clinical practice. It is exactly this lacuna that 
contributed to the scale of the thalidomide disaster and yet pregnant women are still rarely 
included in drug trials. This issue was recently brought to the fore again when during the Ebola 
crisis pharmaceutical companies, governments and humanitarian organisations collaborated 
with remarkable speed to bring Ebola vaccines into clinical trials – and yet, despite the fact that 
pregnant women were particularly vulnerable to Ebola and that perinatal mortality in Ebola has 
been near total, pregnant women were  initially excluded from the trials of the vaccine.(11) This 
situation was remedied, and forcibly illustrated the case made in the ethical guidelines prepared 
by the Council for International Organizations of Medical Sciences (CIOMS) which state that 
“research designed to obtain knowledge relevant to the health needs of the pregnant  woman 
must be promoted”. The STRIDER trials aimed to evaluate sildenafil as a treatment for fetal 
growth restriction – a treatment already creeping into common practice with the backing of 
observational data and physiological plausibility. Stopping the trial in the Netherlands early 
when evidence emerged that sildenafil was actually associated with increased fetal risks has 
changed clinical practice and demonstrates clearly how the responsible conduct of randomised 
controlled trials has protected women and children around the world.(12,13) The blanket 
exclusion of women from studies that offer them and future families important clinical benefits 
arises from a paternalistic determination that women are unable to assess risk for themselves 
and fails to take into account the fact that acceptable risk is contextual and individual, as in the 
Ebola vaccine trials for example. For obstetricians, there is an ethical imperative to advocate for 
the inclusion of pregnant women in clinical research and lead the way in developing responsible 
ethical frameworks to allow women to to make their own informed choices and access the 
benefits of research participation. 
 










Fortunately, most mothers experience uncomplicated pregnancies and even relatively common 
obstetric disorders are rare in comparison to conditions such as diabetes, hypertension, and 
chronic renal disease within the general population. Fetal growth restriction secondary to 
placental insufficiency may be one of the most common conditions presenting to fetal medicine 
specialists, but on a population level it is rare enough to have been awarded orphan drug status 
by the European Medicines Agency (EMA).(14) (Orphan drug status is only available where a 
disease is classified as „rare‟, affecting fewer than 5 in 10,000 Europeans) In a field where 
targeted conditions will be rare, the importance of ensuring all research performed is usable is 
paramount.  
 
In obstetrics we deal with a human imperative stronger than the will to survive – the will to 
reproduce and to protect our offspring. Patient priorities in obstetrics, where the interests of the 
fetus and mother are not always in harmony, are often radically different than in other 
disciplines.(15) Personal and cultural perspectives play a strong role in the interpretation and 
choices of women and their families in challenging clinical scenarios. How can an obstetrician 
determine the relative importance of the risk of a procedural complication for the mother against 
the risk of harm to the fetus from non-intervention? Might the lived experience of making those 
decisions not provide a more valuable form of evidence than the clinicians perspective of 
observing patients pass through these experiences?(16) Where challenging and value laden 
decisions about care are required, as so frequently occurs in high risk obstetrics, we are obliged 
to provide the best possible evidence in the fullest sense of the word, addressing all the 














Patient involvement in research: collaborative priority setting partnerships and patient 
involvement in research design 
 
A traditional paradigm for shared decision making describes taking the best available evidence 
and integrating it with the personal and cultural perspectives of the patient in order to make 
decisions about care. This framing inherently assumes that the evidence itself is unaffected by 
cultural and personal biases, even those of researchers and clinicians who have chosen what 
and how to research. When we acknowledge that this cannot be the case, we must also accept 
that high-quality evidence is not something that researchers generate and present to patients, it 
is evidence produced with and for the people who will be using it.  
 
Consciously opening the process of choosing research directions to as diverse a field of 
stakeholders as possible generates ideas that would not always have been identified as 
priorities for researchers.(17) The James Lind Alliance formally brings together patients and 
healthcare professionals to prioritise the most pressing research uncertainties for this reason. 
The results of priority setting exercises for infertility, preterm birth, and stillbirth generated 
questions covering not only new treatments and technologies, but also addressing topics 
ranging from empowering women to discuss their concerns with care providers to the holistic 
care of families after experiencing adverse outcomes.(18,19) Priority setting exercises across 
obstetrics and gynaecology including hypertension in pregnancy and multiple pregnancies are 
underway. The aim of these partnerships is not to restrict researchers from pursuing genuinely 
novel treatments and technologies, nor to generate questions that could each be addressed in 
discrete trials, but to formalise the core principle that research should serve our patients. By 
establishing as a norm the need to be collaborative in agreeing priority research questions, our 
speciality can ensure that the use and applicability of novel therapies and technologies are 
considered from the very earliest stages of investigation and development. Negative or non-










productive findings shared openly are not research waste – unreported, poorly analysed, 
unnecessarily duplicated or inaccessible research is. Changing the systemic incentives in terms 
of funding, publications and career development that prioritise the publication of statistically 
significant work over important null findings is key to reducing research waste. We should not 
fear to investigate questions where the answer may be „no‟, but we should avoid questions 
where the answer would not matter either way.  
 
The involvement of patients and stakeholders should not end with identifying important research 
questions; their involvement should be central to study design, patient recruitment, and 
participant retention.(15) Involving people with personal experience of the condition to be 
investigated in this way has objectively been shown to improve trial recruitment and retention, 
but is likely to improve the experience of trial participation and utility of the research output in 
ways more difficult to quantify. (20)  We know that the patient agenda is not fully explored in 
most clinical encounters and yet has a major impact on patients choosing to continue or modify 
treatment – research designs that incorporate qualitative exploration of patient experience and 
priorities are more likely to generate information with utility in the real world of multiple concerns 
and priorities.(16) Changing the research design paradigm is not only beneficial for improving 
the quality of research and reducing research waste, it is ethically imperative on the grounds of 
justice, autonomy, and beneficence.  
 
 
Prospective registration and incomplete reporting 
 
A great wealth of patient data as yet unused or with unrealised potential still exists in 
unpublished or incompletely reported randomised controlled trials, and is the subject of the All 
Trials campaign.(21) Around half of all trials are estimated to remain unreported, with academic 










sponsors performing particularly poorly.(22) With this level of performance, it is legitimate to 
wonder if it is ethical to approach women to participate in research at all. Prospective 
registration of trials can ensure more complete reporting of the data, particularly adverse events, 
than in journal publication alone and also allows sponsors and researchers to be held 
accountable for trials started but not reported. (23) Prospective registration and protocol sharing 
for trials is welcome, but when over 90% of published research is observational,(24) to address 
trial registration and reporting alone is to ignore the majority of our evidence base. This is 
particularly true in obstetrics, since the historical exclusion of pregnant women from controlled 
trials leads to an even greater dependence on observational data. Prospective registration is 
recommended in the Strengthening the Reporting of Observational studies in Epidemiology 
(STROBE) guidelines (25) and is feasible in a number of online registries but is not yet common 
practice. It might not be reasonable to expect that all observational studies undertake formal 
registration. There are reasonable concerns that the heterogeneity of methods and purpose of 
observational research makes it impractical to apply a single standard for prospective 
registration to all observational studies and might actually limit exploration of new ideas.(26) 
Major journals have, however, made it clear that they expect large, hypothesis driven 
observational studies to provide protocols and prospective registration in the same way as 
randomised trials.(27)  
 
If the primary evidence base benefits from prospective registration, prospective registration of 
systematic reviews is also important to reduce selective reporting in evidence syntheses. The 
PROSPERO registry of systematic reviews exists to provide accountability and reduce the 
incidence of unnecessarily duplicated reviews.(28) Unfortunately, as demonstrated by the 
recent publication of four systematic reviews on the use of chewing gum after caesarean 
section, all showing a benefit and none yet having a noticeable impact on clinical practice, the 










availability of prospective review protocol registration does not yet preclude research waste in 
this area.(29–33)  
 
Perhaps in addition to requiring that all systematic reviews demonstrate a prospectively agreed 
protocol in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, we should also require study authors to demonstrate a search 
prior to commencing their review for similar ongoing projects and provide evidence for the 
novelty or relevance of their work? (34) Even before systematic reviews, triallists have an 
obligation to consider not only what research priorities exist, but also what is currently known 
and how their work might advance that in the process of developing new studies. Given that 
informal literature reviews are frequently found to be selective and avoid contradictory works, 
the gold standard for this process should be a formal systematic review prior to embarking on a 
new trial. (3) Of three new trials of therapeutic interventions in obstetrics published in this journal 
last year, all made reference to prior work in their field but only one referred to a systematic 
review of the literature on the topic. (35–37) In this one case, the systematic review referred to 
was published after trial recruitment was ended, so clearly was not able to inform trial design – 
why not perform a systematic review during the development of the trial?  
 
Evidence synthesis in obstetrics 
 
While our speciality is drowning in numerous studies of little to no clinical significance and the 
difficulty in comprehensively assessing the breadth of the evidence on any particular question is 
substantial. (38) Research is only of use, no matter how well registered, conducted, and 
reported, if it is accessible to the end user and implemented into clinical practice.(39) The gold 
standard of evidence synthesis is by systematic review and meta-analysis, but limitations in the 
primary studies, both trials and observational reports, the statistical methods of summarising 










findings, and the accessibility of review findings to clinicians and the public can limit their impact 
on clinical practice. (40,41) A number of new approaches are being developed to address the 
limitations of traditional meta-analysis, including the development of core outcome sets, use of 
individual participant data (IPD), umbrella reviews, prospective and network meta-analyses. 
 
Core outcome sets 
A particular challenge in evidence synthesis is heterogeneity in case definitions and outcome 
reporting between studies.(42–45) Consensus definitions ensure that the populations in each 
trial are comparable (46–48) and minimum reporting sets ensure that key population information 
is available in primary reports.(49) Clearly and consistently defining the population investigated 
is key to determining the clinical applicability of trial results and summarising results across 
studies. Recent attention to consensus on the selection, collection, and reporting of outcomes in 
randomised controlled trials has set the stage for new work that will use core outcome sets in 
order to increase transparency, accessibility, and ease of evidence synthesis.  
 
The Core Outcomes in Women‟s and Newborn Health (CROWN) initiative is a collaboration of 
over 80 speciality journals, including Ultrasound in Obstetrics and Gynecology, that has 
established the importance of core outcome sets  and have committed to supporting their 
development, dissemination, and implementation. (38,50) The Core Outcome Measures in 
Effectiveness Trials (COMET) initiative allows prospective registration of core outcome sets 
development, and 98 projects are registered within obstetrics and gynaecology, just under 10% 
of the entire registry. Core outcome sets have been developed for a range of conditions relevant 
to obstetrics, including pre-eclampsia, preterm birth, and twin-to-twin transfusion syndrome.(51–
56) In core outcome set development healthcare professionals, researchers, patients, and 
others come together to agree the outcomes that will be most useful. It is important these core 
outcome sets are developed using robust consensus science methods to ensure they do reflect 










the perspectives of key stakeholders.(57) Embedding this perspective should prevent the 
practice of p-hacking, which is the selective reporting of outcomes or analyses based upon 
statistical significance,(58) and inadequate reporting of harms.(59,60) Such issues have been 
identified across a broad range of conditions relevant to obstetrics and maternity care.(61–63) 
 
Individual participant data meta-analysis 
Data reported in international trial registries not only promotes accountability and complete 
reporting, but allows researchers to avoid the limitations of heterogenous study quality, case 
definitions, and outcome reporting in primary study reports by returning to the raw data originally 
collected for evidence synthesis.(64)  The use of individual participant data (IPD) in evidence 
synthesis allows increasing sample size, investigation of the interaction of individual patient 
factors with treatment response and the consideration of outcomes not necessarily included in 
the primary study reports. IPD meta-analysis (IPD-MA) has been described as the „gold 
standard‟ for evidence synthesis because it enables full use of all collected data and 
standardisation of variables across studies, but the analysis can be costly and time consuming 
to undertake. 
 
Although there are resource and training requirements for IPD-MA, in practice the most 
significant barriers are limitations on access to primary data.(65) Most researchers support 
responsible data sharing but the response to real requests for data is rather less enthusiastic. 
(64) In one analysis focusing on prediction of pre-eclampsia, 176 eligible studies were identified 
through a systematic literature search, but only 30 datasets were ultimately made available for 
analysis, with only 46% of authors contacted responding and many of those ultimately not 
sharing their data or finding the data unusable.(66) In two cases, institutional data custodians 
actually blocked data sharing.  
 










Research funding bodies and journals are leading change with respect to supporting trial 
registration and data sharing – from 2013 the BMJ has only published new trials where a 
commitment to reasonable data sharing is present  and the International Committee of Medical 
Journal Editors (ICMJE) has formally endorsed the position that sharing anonymised individual 
data is ethically mandated and is moving to change culture in their journals in support of more 
collaborative working. (67)(68) In obstetrics, where the benefits of shared data are so significant 
and the ethical imperative so strong, we should be leaders in the development of innovative 
models for collaboration that both harness the power of unused data and recognise the work of 
the researchers who designed and collected the original data. A useful example is the 
International Prediction of Pregnancy Complications (IPPIC) Network, bringing together more 
than 70 researchers from 21 countries who have contributed data from over 2 million 
pregnancies to be investigated using IPD-MA.(69) With journals and funders increasingly unified 





New horizons for systematic reviews and meta-analyses 
An integral part of the IPPIC initiative has been the publication of a comprehensive review of all 
the published systematic reviews on screening for preeclampsia, which highlighted the ongoing 
unnecessary repetition of small studies with heterogenous case definitions and outcomes 
hindering further development in this field.(70) This form of „umbrella review‟ provides a broad 
overview of the evidence and if rigorously performed should incorporate an assessment of the 
degree of confidence in findings of individual reviews that can usefully inform the decision 
making of individual patients.  
 










Network meta-analysis allows indirect as well as direct comparison of existing treatments, 
enabling reviewers to compare a wider range of treatments. Recent examples include a large 
Cochrane review of uterotonics for post-partum haemorrhage (PPH)(71) and a network meta-
analysis of labour induction methods.(72) In both these areas trials and observational studies 
abound, but rarely compare more than two or three interventions. The network meta-analysis 
permits a broader overview of the field and comparison of interventions than a traditional meta-
analysis would permit, but requires relatively complex statistical input to achieve.   
 
A key problem for meta-analysis is that commonly only published trials are available to be 
included, and the results of the trials are known prior to the initiation of evidence synthesis. A 
prospective meta-analysis attempts to address this, using the increasing fact of prospective trial 
registration to facilitate searching for and identifying eligible trials prior to completion and 
planning the meta-analysis, including any sub-group analysis, prospectively. 
 
Data sharing for evidence synthesis 
Open data does not only apply to trials but given that data storage is typically of higher quality in 
trials than in observational studies, access to high quality trial data is the right place to start. The 
next ambition should be to stop throwing away valuable data on outcomes on rare conditions in 
pregnancy by leaving routinely collected pregnancy data buried in mismatching hospital 
electronic records or small single centre cohort studies reporting varying outcomes with varying 
lengths of follow up. When rare conditions are investigated, single centres rarely have enough 
cases to identify uncommon outcomes or the interaction of treatment choices with patient 
factors and the effect on clinical outcomes. National or regional registries for rare diseases, 
including the Twin and Multiple Birth Association (TAMBA) funded national registry for 
complicated twin pregnancies or those designed for the capture of rare outcomes(73) could 
increase the number of cases available for analysis. With prospective registration and rigorous 










follow up they offer the potential for exploring factors modifying treatment effects, rare harms 
from treatment and valuable avenues for future trials. (74) (75) 
 
 
A call to action 
 
Obstetricians are rightly proud of the work being done to reduce research waste in our field. We 
can point to examples including the CROWN initiative and numerous priority setting projects 
leading the way in promoting collaborative working, prioritising productive research, and 
ultimately improving the information and care we can provide to mothers and babies.  Still, there 
is much work to do and many systemic barriers to dismantle to achieve the goal of „less 
research, better research, done for the right reasons‟ (Figure 2).(76)  
 
We need to consider cultural change across the board from funders, institutions and 
researchers to dismantle the system features that promote poorly conducted, incompletely 
reported, and ultimately wasted research. Increasing transparency, from the initiation and 
design of studies right through to the peer review of final reports is likely to be a key component 
of this culture change. The use of prospective registration of trials and systematic reviews, a 
collaborative approach to data sharing, innovative methods of evidence synthesis, and 
promotion of complete and accessible study reporting are all important priorities. The critical 
change we all need to make however, is placing mothers and babies at the centre of every 
process in research design, production, dissemination, and implementation. We have begun to 
realise the vision of woman centred care in clinical obstetrics: woman centred research should 
be the rule in developing the evidence base to support this care.  
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o Over 80% of all research is wasted through poorly selected research questions and 
conduct of studies, incomplete reporting, delayed evidence synthesis and lack of 
translation to clinical practice.  
o This problem is particularly important in obstetrics where pregnant women have 
historically been neglected in primary studies and treatment decisions; taking into 
account the needs of both mother and fetus are particularly complex. 
o Many new initiatives are working to reduce research waste across clinical medicine 
and in obstetrics specifically including requiring prospective registration of trials and 
observational studies, promoting data sharing and high quality evidence synthesis and 
dissemination.  
o The key to the cultural change that is required in obstetric research is placing mothers 
and babies at the centre of every process in research design, production, 
dissemination, and implementation.  
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